Update on the management of STEMI. Elliot Rapaport, M.D. San Francisco, CA December 14, 2007
|
|
- Clifton Pearson
- 5 years ago
- Views:
Transcription
1 Update on the management of STEMI Elliot Rapaport, M.D. San Francisco, CA December 14, 2007
2 Universal MI Definition Committee 2007 Recommendations Type 1 Spontaneous MI associated with ischemia and due to a primary coronary event such as plaque erosion, rupture, fissuring, or dissection. Type 2 Due to an imbalance between supply and demand of oxygen. Result of ischemia but not ischemia from thrombosis of coronary artery. Type 3 Sudden cardiac death, including cardiac arrest, with symptoms of ischemia, accompanied by new ST elevation or LBBB. Verified coronary thrombus by angiography or autopsy but death occurring before blood samples could be obtained or before biomarkers appear in the blood Type 4 MI associated with PCI. PCI-related increase of biomarkers (assuming a normal troponin baseline) greater than 3X 99 th percentile of the upper reference limit is by convention defined as MI. Type 4b-MI associated with verified stent thrombosis via angiography or autopsy. Type 5 MI associated with CABG (> 5X 99 th percentile upper reference) limit plus new Q waves or LBBB or imaging evidence of new loss.
3 Primary PCI vs Thrombolysis in STEMI: Meta-analysis Short-term Outcomes P< Randomized Clinical Trials N = 7739 Frequency (%) P=.0002 P<.0001 P=.032 P<.0001 PTCA Thrombolytic therapy 5 P< Death Nonfatal MI Recurrent Ischemia Hemorrhagic Stroke Major Bleed Death, Nonfatal Reinfarction, or Stroke Note: When primary PCI is compared to alteplase and the SHOCK trial is excluded, mortality is 5.5% v 6.7%, p=0.081 STRIVE TM
4 PG.Steg 0105 NRMI-2: Primary PCI door-to-balloon time vs mortality 10 N=27,080 P< Mortality (%) >180 Door-to-balloon time (minutes)
5 Reperfusion I I IIa IIb III IIa IIb III STEMI patients presenting to a hospital with PCI capability should be treated with primary PCI within 90 minutes of first medical contact. Modified recommendation STEMI patients presenting to a hospital without PCI capability and who cannot be transferred to a PCI center for intervention within 90 minutes of first medical contact should be treated with fibrinolytic therapy within 30 minutes of hospital presentation, unless contraindicated. Modified recommendation
6 Meta-Analysis of 17 Facilitated PCI Trials* Event Facilitated PCI (%) PCI (%) P Death Reinfarction Urgent TVR Major bleeding Stroke *Includes 9 GP IIb/IIIa inhibitor trials (n=1148); 6 thrombolytic therapy trials (n=2957); 2 combination therapy trials (n=399) Keeley EC. Lancet. 2006;367: STRIVE TM
7 600 patients randomized
8
9
10 Facilitated PCI I IIa IIb III Facilitated PCI using regimens other than full-dose fibrinolytic therapy might be considered as reperfusion strategy when the following are present: Patients at high risk PCI is not immediately available within 90 minutes Bleeding risk is low Younger age Absence of poorly controlled hypertension Normal body weight Modified recommendation I IIa IIb III A planned reperfusion strategy using full-dose fibrinolytic therapy followed by immediate PCI may be harmful. Modified recommendation
11 Four-year cumulative event rates in OAT Outcome PCI (%) Medical (%) HR 95% CI p Death, MI, HF All MI Nonfatal MI NYHA class 4 HF Death ,166 STEMI patients randomized 3 to 28 days after AMI Hochman JS et al. N Engl J Med 2006;
12 TOSCA-2 2 Trial: Primary Endpoint 5% 4% 3% 2% 1% 0% Change in LV Ejection Fraction at One Year (% increase) n = 195 p=0.47 n = % 3.5% PCI Medical Therapy ( 83% patency at 1 yr ) ( 23% patency at 1 yr ) Change in LV ejection fraction (LVEF) at one year did not differ between the PCI and medical therapy group (4.2% increase with PCI vs. 3.5% increase with medical therapy, p=0.47). www. Clinical trial results.org Dzavik, V et al. Presented Circulation; AHA Nov
13 PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion I IIa IIb III PCI of a hemodynamically significant stenosis in a patent infarct artery greater than 24 hours after STEMI may be considered as part of an invasive strategy. Modified recommendation I IIa IIb III PCI of a totally occluded infarct artery greater than 24 hours after STEMI is not recommended in asymptomatic patients with one- or two-vessel disease if they are hemodynamically stable and do not have evidence of severe ischemia. New recommendation
14 Meta-Analysislsis:: Stenting vs Balloon for STEMI(13RCT s; n=6921) 12- month MORTALITY STUDY WITHOUT ABCIXIMAB I II STENTING BALLOON n/n (%) n/n (%) OR (fixed) 95% CI Weight % OR 95% CI P value CADILLAC 17/512 (3.3%) 28/518 (5.4%) [0.32, 1.11] 1.0 FRESCO 1/75 (1.3%) 4/75 (5.3%) [0.03, 2.20] 0.36 Jacksch et al 5/231 (2.2%) 7/231 (3.0%) [0.22, 2.26] 0.56 PAMI 26/452 (5.8%) 14/448 (3.1%) [0.97, 3.67] PASTA 3/67 (4.5%) 6/69 (8.7%) [0.12, 2.05] 0.49 PSAAMI 4/44 (9.1%) 8/44 (18.2%) [0.12, 1.62] 0.35 STENTIM-2 3/101 (3.0%) 2/110 (1.8%) [0.27, 10.1] 0.58 ZWOLLE-5 3/112 (2.7%) 4/115 (3.5%) [0.17, 3.49] 1.0 ZWOLLE-6 47/785 (6.0%) 45/763 (5.9%) [0.67, 1.55] 0.94 WITHI ABCIXIMAB II STOPAMI-3 25/305 (8.2%) 28/306 (9.2%) [0.50, 1.56] 0.67 STOPAMI-4 7/90 (7.8%) 11/91 (12.1%) [0.23, 1.66] 0.33 CADILLAC 28/524 (5.3%) 16/528 (3.0%) [0.97, 3.38] ABCIXIMAB 60/919 (6.5%) 55/925 (5.9%) [0.76, 1.61] 0.6 CONTROL 109/2379 (4.6%) 118/2373 (5.0%) [0.70, 1.20] 0.5 TOTAL (95% CI) 169/3298 (5.1%) 173/3298 (5.2%) [0.78, 1.21] 0.81 De De Luca, Luca, Suryapranatarrt, Suryapranatarrt et al. et al. JACC 2006t l I JACC 2006l. STENT BETTER BALLOON BETTER STENT BETTER BALLOON BETTER
15 Randomized Trials of DES vs BMS for AMI TVR Odds Ratio ti P (95% C.I.) Value Strategy 0.29 (0.11, 0.11) Typhoon 0.38 (0.22, 0.66) SESAMII 0.35 (0.15, 0.81) Passion (TLR)i () 0.70 (0.36, 1.34) Combinedi 0.43 (0.30, 0.61) <
16 Randomized Trials of DES vs BMS for AMI Odds Ratio P (95% C.I.) Value Death Strategy 0.88 (0.30, 2.53) 0.81 Typhoon 1.01 (0.37, 271) 0.99 SESAMI 0.25 (0.03, 2.22) 0.37 Passion 0.70 (0.35, 1.42) 0.32 Combined 0.75 (0.46, 1.22) 0.24 MI Strategy 0.74 (0.25, 2.23) 0.59 Typhoon 0.80 (0.21, 3.01) 1.00 SESAMI Passion 0.85 (0.26, 2.28) 0.79 Combined 0.80 (0.40, 1.58) 0.51 Stent Thrombosis Strategy 0.25 (0.01, 5.56) 0.34 Typhoon 0.93 (0.42, 2.06) 0.85 Passion 1.02 (0.20, 5.11) 1.00 Combined 0.86 (0.47, 1.56) Grines,C. AHA Nov 2007
17 GRACE Registry Mortality Rates Comparing 569 Patients Receiving DES with 1,729 Patients Receiving BMS During PCI for Acute Myocardial Infarction End point Hazard Ratio Death, d Death, d 4.67 Death, d, 6.02 adjusted for GRACE risk score* Death, d, adjusted for 5.81 GRACE risk score and propensity* STRIVE TM
18 Effect of Clopidogrel on 24-Month Events in Patients Who Were Event-Free at 6 Months* 24-Month Events Eisenstein EL et al. JAMA. 2007;297: With Without Clopidogrel Clopidogrel Drug-Eluting Stent (DES) Patients (n) Difference (95% CI) P Value Death 2.0% 5.3% -3.3% (-6.3%( to -0.3%) 0.03 Death or MI 3.1% 7.2% -4.1% (-7.6%( to -0.6%) 0.02 Bare-Metal Stent (BMS) Patients (n) 417 1,976 Death 3.7% 4.5% -0.7% (-2.9%( to 1.4%) 0.50 Death or MI 5.5% 6.0% -0.5% (-3.2%( to 2.2%) 0.70 *Exclusions: DES (Death 62, nonfatal MI 18, revasc 76, meds not reported 129 (total 285/1502) BMS (Death 123, nonfatal MI 94, revasc 289, meds not reported 266 (total 772/3165)
19 Harmonizing Outcomes with Revascularization and Stents in AMI 3400* pts with STEMI with symptom onset 12 hours Aspirin, thienopyridine UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) R 1:1 Bivalirudin monotherapy (± provisional GP IIb/IIIa) Emergent angiography, followed by triage to CABG Primary PCI Medical Rx 3000 pts eligible for stent randomization R 1:3 Bare metal stent TAXUS paclitaxel-eluting eluting stent *To rand 3000 stent pts Clinical FU at 30 days, 6 months, 1 year, and then yearly through 5 years
20 ExTRACT-TIMI 25: Protocol Design STEMI < 6 h Lytic eligible ASA Lytic choice by MD (TNK, tpa, rpa, SK) Enoxaparin (N=10,256) < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) 75 y: No bolus SC 0.75 mg / kg q 12 h (Hosp DC) CrCl < 30: 1.0 mg / kg q 24 h Double-blind, double-dummy UFH (N=10,223) 60 U / kg bolus (4000 U) Inf 12 U / kg / h (1000 U / h) Duration: at least 48 h Cont d at MD discretion Day 30 1 Efficacy End Point: Death or Nonfatal MI 1 Safety End Point: TIMI Major Hemorrhage ExTRACT=Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction. Antman EM et al. N Engl J Med. 2006;354: Adapted with permission from STRIVE TM
21 % Main Results From ExTRACT TIMI 25 Primary End Point: Death or nonfatal re-mi by 30 days RR=0.83 P<.001 UFH ENOX % Main Secondary End Point: Death, nonfatal re-mi, or urgent revascularization by 30 days RR=0.81 P<.001 UFH ENOX Days Days RR=0.88 P= Major bleeding at 30 days: 1.4% with UFH vs 2.1% with enoxaparin (P<.001) ICH: 0.7% for UFH vs 0.8% for enoxaparin (P=.14) Adapted with permission from Antman EM, et al. N Engl J Med. 2006;354: STRIVE TM
22 ExTRACT-TIMI 25 PCI Cohort: Primary End point Death or Nonfatal MI by 30 days Death or MI (%) ,404 Underwent PCI by 30 days 24.2% RR 0.77 P=0.001 EVENT ENOX UFH RR 5 2,272 Underwent PCI by 30 days 22.8% Days UFH 13.8% ENOX 10.7% TIMI Major Bleed 1.4% 1.6% 0.87 ( ).56 TIMI Minor Bleed 3.3% 2.4% 1.34 ( ).09 ICH 0.2% 0.4% 0.42 ( ).18 Stroke 0.3% 0.9% 0.30 ( ).006 P Gibson M. Presented at World Congress of Cardiology; September 4, 2006; Barcelona, Spain. Adapted with permission from STRIVE TM
23 Anticoagulants as Ancillary Therapy I IIa IIb III Patients undergoing reperfusion with fibrinolytics should receive anticoagulant therapy for a minimum of 48 hours, and preferably for the duration of the index hospitalization, up to 8 days. New Recommendation I IIa IIb III Regimens other than UFH are recommended if therapy is given for more than 48 hours because of risk of heparin-induced induced thrombocytopenia. New Recommendation Regimens with established efficacy include: UFH, enoxaparin, fondaparinux (see full text Update for dosing recommendations)
24 CLARITY TIMI 28: Study Design Double-blind, randomized, placebo-controlled trial in 3491 patients, aged yrs, with STEMI <12 hours Fibrinolytic, ASA, Heparin Randomized Study Drug Open-label clopidogrel per MD in both groups Clopidogrel 300 mg + 75 mg qd Coronary Angiogram (2-8 days) 30-day clinical follow-up Placebo Primary end point: Occluded artery (TIMI flow grade 0/1) or death/mi by time of angio Sabatine MS, et al. N Engl J Med. 2005;352: STRIVE TM
25 CLARITY TIMI 28: End Points Primary End Point Occluded Artery (or Death/MI Through Angio/HD) CV Death, MI, RI Urg Revasc Occluded Artery or Death/MI (%) % Odds Reduction n=1752 n=1739 Clopidogrel Placebo Endpoint (%) Placebo Days Clopidogrel Odds Ratio: 0.80 (95% CI, ) P=.03 20% Sabatine MS, et al. N Engl J Med. 2005;352: Note: No increase in major or minor bleeding or ICH seen STRIVE TM
26 COMMIT: Effect of Clopidogrel on Death, Re-MI, or Stroke Placebo + ASA: 2311 events (10.1%) Placebo + ASA: 1846 deaths (8.1%) Clopidogrel + ASA: 2125 events (9.3%) 7 6 Clopidogrel + ASA: 1728 deaths (7.5%) Event (%) % (SE3) relative risk reduction (P=.002) Mortality (%) % (SE3) relative risk reduction (P=.03) Days Since Randomization (up to 28 days) Days Since Randomization (up to 28 days) COMMIT Collaborative Group. Lancet. 2005;366: Note: No increase in major bleeding or ICH was seen STRIVE TM
27 Clopidogrel I I I IIa IIb III IIa IIb III IIa IIb III For all post-pci patients receiving a DES, clopidogrel 75 mg daily should be given for at least 12 months, if not at high risk of bleeding. b For post-pci patients receiving a BMS, it should be given for a minimum of 1 month and ideally up to 12 months (unless patient is at increased risk of bleeding). Modified recommendation For all STEMI patients not undergoing a stent placement (medical therapy alone or PTCA without stenting), treatment with clopidogrel should continue for at least 14 days. New recommendation Long-term maintenance therapy (e.g. 1 year) with clopidogrel is reasonable in STEMI patients, regardless of whether or not they undergo reperfusion therapies. New recommendation
28 COMMIT: Effects of METOPROLOL on Death in hospital Placebo: 1798 deaths (7.8%) Metoprolol: 1776 deaths (7.7%) % dead 1% (SE 3) relative risk reduction (2P=0.7) Days since randomisation
29 COMMIT: Effects of METOPROLOL on Death by attributed cause(s) Cause(s) Metoprolol Placebo Odds ratio & 95% CI (22,927) (22,922) Metop. better Placebo better Arrhythmia 388 (1.7%) 498 (2.2%) 22% SE 6 Shock 496 (2.2%) 384 (1.7%) -29% SE 8 Other causes 892 (3.9%) 916 (4.0%) 3% SE 5 ANY DEATH 1776 (7.7%) 1798 (7.8%) 1% SE 3 (2P > 0.1; NS)
30 Effects of iv then oral β-blocker on reinfarction in 3 major trials of acute MI Trial ß-blocker Control Odds ratio & 95% CI (33,841) (33,813) ß-blocker better Control better MIAMI 85 (3.0%) 111 (3.8%) ISIS (1.8%) 161 (2.0%) COMMIT 467 (2.0%) 568 (2.5%) OVERALL 700 (2.1%) 840 (2.5%) 17% SE 5 (2P = )
31 Beta-Blockers Blockers I IIa IIb III Oral beta-blocker blocker therapy should be initiated in the first 24 hours for patients who do not have the following: Signs of heart failure Evidence of low output state Increased risk for cardiogenic shock Age >70 years Systolic blood pressure <120 mm Hg Sinus tachycardia (heart rate >110 or < 60 bpm) Increased time since onset of symptoms of STEMI Relative contraindications to beta-blockade blockade PR interval >0.24 seconds second- or third-degree degree heart block active asthma or reactive airway disease Modified recommendation
32 Beta-Blockers Blockers I IIa IIb III It is reasonable to administer an IV beta-blocker blocker at the time of STEMI presentation to patients who are hypertensive and who do not have any of the following: Signs of heart failure Evidence of low output state Increased risk for cardiogenic shock Other relative contraindications to beta-blockade blockade (text modified) No change in recommendation (text modified) I IIa IIb III IV beta blockers should not be administered to patients who have any of the following: Signs of heart failure Evidence of low output state Increased risk of cardiogenic shock Other relative contraindications to beta-blockade blockade New recommendation
33 : Primary Endpoints EPHESUS Trial: Primary Endpoints n = 6,632 AMI with HF and LVEF< 40 20% 15% All-cause Mortality Mean FU 16 mos RR % p= % 14.4% 30% CV Death or Hospitalization RR 0.83 p= % 26.7% 10% 20% 5% 10% 0% 0% Eplerenone Placebo Note: www. RR Clinical 0.69 trial (CI ), results.org p=.004 at 30 days Eplerenone Placebo N Engl J Med 2003;348:
34 Kaplan-Meier estimates of the rate of all-cause mortality at 30 days in EPHESUS 37% RRR of Sudden Death Note: All the benefit was seen in patients randomized between 3 and 7 days. No benefit was seen in 30d mortality if randomized between 8 and 14 d. Zannad, F. ACC Mar 2007 Pitt, B. et al. J Am Coll Cardiol 2005;46:
35 Aldosterone Blockade Use of aldosterone blockade in post-mi patients without significant renal dysfunction or hyperkalemia is recommended in patients who: I IIa IIb III are already receiving therapeutic doses of ACE inhibitor and beta blocker an have a LVEF of less than or equal to 40% have either diabetes or HF Modified recommendation
36 Managing STEMI in 2007: Summary Acute therapy focuses on reperfusion and antithrombotic therapy PCI generally preferred over fibrinolysis when a skilled PCI lab is available with surgical backup and door-to-balloon time is <90 min. Also, in all patients with symptoms for > 3 hours. Fibrinolysis generally preferred when invasive strategy is not an option or when delay to PCI is anticipated (>90 min door-toballoon) in patients presenting within 3 hours of onset. Current ACC/AHA STEMI guidelines recommend IV UFH as ancillary therapy to reperfusion therapy (Class I) ExTRACT-TIMI 25 showed enoxaparin superior to current standard of UFH as the antithrombin to support fibrinolysis. An increase in bleeding with enoxaparin vs UFH is outweighed by an overall net clinical benefit in favor of enoxaparin Clopidogrel on top of aspirin results in significant further improvement in the reperfusion of STEMI patients either with fibrinolysis (CLARITY/COMMIT) or with PCI. STRIVE TM
37 Summary: STEMI (continued) Facilitated PCI with full dose lytic worse outcome Rescue PCI benefit for failed lysis Bivalirudin appears superior to UHF + GPiib/iiia for PCI (HORIZON trial) Recanalization of a total residual occlusion after fibrinolysis in an asymptomatic patients is unwarranted Fondaparinux: D/MI vs placebo; = D/MI vs UFH; no difference in bleeding. However, increase in guiding catheter thrombosis At present, use of a BMS seems preferable to DES. Diabetic patient may be an exception because of high restenosis rate Prasugrel not yet ready for prime time Start Eplerenone on top of ACEI and BB between day 3 and 7 if early HF symptoms occured and LVEF <40 STRIVE TM
A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationPathophysiology of ACS
Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792
More informationThe Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium
The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationIssues in the Management of Diabetic Patients with Cardiovascular Disease
Issues in the Management of Diabetic Patients with Cardiovascular Disease Elliot Rapaport, MD December 13, 2008 1 Hyperglycemia and Acute Coronary Syndromes 2 Effect of Hyperglycemia in STEMI Impairs microvascular
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationDISCUSSION QUESTION - 1
CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationPPCI in STEMI. ESC at the 22nd Annual Conference of the Saudi Heart Association February 21th, 2011
PPCI in STEMI Dr Hassan Mhish Interventional Cardiology Consultant Cardiology Fellowship Program Director Prince Salman Heart Center King Fahd Medical City Riyadh, KSA ESC at the 22nd Annual Conference
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationAcute Coronary Syndrome: Interventional Strategy
2005 Acute Coronary Syndrome: Interventional Strategy Youngkeun Ahn, MD, PhD, FACC, FSCAI Department of Cardiology Program in Gene and Cell Therapy, The Heart Center of Chonnam National University, GwangJu,,
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationOptimal antithrombotic therapy:
Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationEarly Management of Acute Coronary Syndrome
Early Management of Acute Coronary Syndrome Connie Hess, MD, MHS University of Colorado Division of Cardiology Acute Coronary Syndrome (ACS) A range of conditions associated with sudden imbalance in myocardial
More informationFrom STEMIs to Stents: Updates in PCI practice
From STEMIs to Stents: Updates in PCI practice Arnold Seto, MD, MPA Assistant Clinical Professor, UC-Irvine and Long Beach VA Director of Interventional Cardiology Research Hospitalizations in the U.S.
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationWhat is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI
More informationST-Elevation MI: Update on Bivalirudin and DES
ST-Elevation MI: Update on Bivalirudin and DES George D. Dangas, MD, FACC, FSCAI, FAHA Professor of Medicine Director, Cardiovascular Innovation Mount Sinai Medical Center, New York, NY Disclosure Research
More informationThrombolysis, adjunctive pharmacology and interventions
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation ESC Annual Congress Munich, 2012 Thrombolysis, adjunctive pharmacology and interventions
More informationThrombolysis in Acute Myocardial Infarction
CHAPTER 70 Thrombolysis in Acute Myocardial Infarction J. S. Hiremath Introduction Reperfusion of the occluded coronary artery at the earliest is the most important aim of management of STEMI. Once a flow
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationST ELEVATION MYOCARDIAL INFARCTION
ST ELEVATION MYOCARDIAL INFARCTION Doron Zahger, MD Dept. of Cardiology, Soroka University Medical Center Faculty of Health Sciences, Ben Gurion University of the Negev MAIN TOPICS Adjuncts to thrombolysis
More informationClopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent
Clopidogrel When For What For How Long T Benjanuwattra Chiang Mai Heart Cent Evidence Based Medicine I don t want to put you to sleep But want you to be fully alert Atherothrombosis: A Generalized and
More informationUpdate on STEMI Guidelines. Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center
Update on STEMI Guidelines Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center All Rights Reserved, Duke Medicine 2008 Disclosures Research Grants: NHLB, AHRQ, AstraZeneca,
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAcute Coronary Syndrome
Acute Coronary Syndrome Vik Gongidi, DO FACOI, FACC Indian River Medical Center Vero Beach, FL Slides adapted from Robert Bender, DO, FACOI, FACC Definition: Acute Myocardial Ischemia Unstable Angina Non-ST-Elevation
More information2018 Acute Coronary Syndrome. Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute
2018 Acute Coronary Syndrome Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute Definitions: Acute Myocardial Ischemia Unstable Angina Non-ST-Elevation MI (NSTEMI) }2/3 ST-Elevation
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationSTEMI Primary Percutaneous Coronary Intervention
STEMI Primary Percutaneous Coronary Intervention Abdul Razek Maaty, MD Professor of Medicine Outline Primary PCI Aspiration, manual thrombectomy and distal protection devices Choice of stent Pharmacothaerpy,
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationST-elevation myocardial infarctions (STEMIs)
Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve
More information2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers
More informationACUTE CORONARY SYNDROME PCI IN THE ELDERLY
ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.
More informationPrimary PCI in patients with STEMI Abbott Vascular. All rights reserved.
Primary PCI in patients with STEMI Primary PCI in patients with STEMI Agenda 2 Primary PCI in patients with STEMI Definition: angioplasty ± stenting without prior or concomitant fibrinolytic therapy Objectives
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationPatient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough
Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough Current Management Strategies for ACS ACS No ST Elevation ST ST Elevation Elevation Early Invasive Early Conservative Fibrinolysis
More informationPrimary PCI State of the Art. A/Prof Michael Nguyen Fremantle Hospital/Fiona Stanley Hospital Perth Australia JCR Meeting Busan 2014
Primary PCI State of the Art A/Prof Michael Nguyen Fremantle Hospital/Fiona Stanley Hospital Perth Australia JCR Meeting Busan 2014 Content Evidence of Primary PCI vs Thrombolysis When, Why, How Transfer
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationACC/AHA 2007 STEMI Guidelines Focused Update Slide Set
ACC/AHA 2007 STEMI Guidelines Focused Update Slide Set Based on the 2007 Focused Update of the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (STEMI): A Report
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationStent Thrombosis Importance of Pharmacotherapy
Stent Thrombosis Importance of Pharmacotherapy George D. Dangas, MD, FSCAI Columbia University Medical Center Cardiovascular Research Foundation New York City SCAI-2007 Orlando, FL Presenter Disclosure
More informationNSTEACS Case Presentation
NSTEACS Case Presentation Shaul Atar, MD Director of Cardiology Western Galilee Hospital Nahariya Dan Caesrea, 2010 Case Presentation 64 Y. old male HLP, HTN, smoker Prolonged typical CP at rest, multiple
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationThe Role of Enoxaparin Across ACS Spectrum
SYP.ENO.16.08.01 The Role of Enoxaparin Across ACS Spectrum dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Optimum Anticoagulation in ACS patients : Summary from Guidelines Role of Enoxaparin in ACS Spectrum
More informationJoo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationSTREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve
STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION PCI Hospital Ambulance/ER STREAM design STEMI
More informationUPDATE ACUTE CORONARY SYNDROMES. Dr. Wayne Tymchak April 7, 2017
UPDATE ACUTE CORONARY SYNDROMES Dr. Wayne Tymchak April 7, 2017 Spontaneous Rupture Unstable Angina Myocardial Infarction Classification: Acute Coronary Syndromes Ischemic Discomfort Non-ST ST Unstable
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More information2010 ACLS Guidelines. Primary goals of therapy for patients
2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in
More informationManagement of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police
Management of STEMI in era of Reperfusion Eagles 2007 Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police STEMI in US ST Segment Elevation Myocardial Infarction (STEMI) ~500 K per year Thrombolysis
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationIs there a real need for new agents to optimize efficacy/safety balance
Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures
More informationTreatment of Acute Coronary Syndromes
Treatment of Acute Coronary Syndromes UC SF Jeffrey Tabas, M.D. sf g h Associate Professor UCSF School of Medicine Emergency Services, San Francisco General Hospital Objectives Review the updated AHA/ACC
More informationThrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology
Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology UNIVERSITY OF AARHUS 1 COI Speakers fee: Aspen, AZ, Bayer, BMS/Pfizer Departmental research grant:
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More information